Nonorganic Insomnia in Generalized Anxiety Disorder

Neuropsychobiology

Volumn 36, Issue 3, 1997, Pages 130-152

  Saletu, Bernd ^a   Saletu Zyhlarz, Gerda ^a   Anderer, Peter ^a   Brandstätter, Nadja ^a   Frey, Richard ^a   Gruber, Georg ^a   Klösch, Gerhard ^a   Mandl, Magdalene ^a   Grünberger, Josef ^a   Linzmayer, Leopold ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Electroencephalographic mapping; Generalized anxiety disorder; Hypnotic and anxiolytic effects; Lorazepam; Lorazepam diphenhydramine combination; Nonorganic insomnia; Noopsyche; Polysomnography; Somnium ; Subjective sleep and awakening quality; Thymopsyche

Indexed keywords

ANXIOLYTIC AGENT; DIPHENHYDRAMINE; LORAZEPAM; SOMNIUM;

ADULT; AGED; ALERTNESS; ALPHA RHYTHM; ANXIETY NEUROSIS; ARTICLE; ATTENTION; BETA RHYTHM; BRAIN FUNCTION; BRAIN MAPPING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL FLICKER FUSION; DELTA RHYTHM; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERANCE; ELECTROENCEPHALOGRAPHY; FATIGUE; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; INSOMNIA; LATENT PERIOD; MALE; MOTOR PERFORMANCE; ORAL DRUG ADMINISTRATION; POLYSOMNOGRAPHY; PRIORITY JOURNAL; PSYCHOMETRY; RATING SCALE; RESPONSE TIME; SLEEP WAKING CYCLE; THETA RHYTHM; TREATMENT OUTCOME; VERTIGO; WAKEFULNESS;

ADULT; AGED; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; AROUSAL; ATTENTION; BRAIN MAPPING; CEREBRAL CORTEX; DIPHENHYDRAMINE; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; ELECTROENCEPHALOGRAPHY; FEMALE; FLICKER FUSION; HUMANS; HYPNOTICS AND SEDATIVES; LONGITUDINAL STUDIES; LORAZEPAM; MALE; MIDDLE AGED; POLYSOMNOGRAPHY; REACTION TIME; SAMPLE SIZE; SINGLE-BLIND METHOD; SLEEP INITIATION AND MAINTENANCE DISORDERS; SLEEP STAGES; TREATMENT OUTCOME;

EID: 8544270081     PISSN: 0302282X     EISSN: 14230224     Source Type: Journal    
DOI: 10.1159/000119374     Document Type: Article

References (68)

1. Kupler DJ, Reynolds CF III: Management of insomnia, N Engl Med 1997:336:341-346.
2. Shader RI, Grcenblatt DJ: The pharmacotherapy of acute anxiety, A mini-update: in Bloom FE, Kupfcr DJ (eds): Psychopharmacology: The Fourth Generation of Progress, New York, Raven Press, 1995. pp 1341-1348.
3. Schweizer E, Rickels K, Uhlenhuth EH: Issues in the long-term treatment of anxiety disorders: in Bloom FE, Kupfer DJ (eds): Psychopharmacology: The Fourth Generation of Progress, New York, Raven Press, 1995. pp 1349-1359.
4. Borbely AA: Die Bceinfiussung des Schlafs durch I lypnotika; in Berger M (ed): Handbuch des normalen und gestorten Schlafs, Berlin, Springer, 1992. pp 120-139.
5. American Psychiatric Association: Task Force Report: Benzodiazepine Dependence, Toxicity and Abuse, Washington, American Psychiatric Association, 1990.
6. Widauer JO: Lorazepam-haltiges Schlafmittcl, Patentschrift DE 3404316 Cl, Munich, Deutsches Patentamt, 1985.
7. Sunshine A, Zighelboim J, Laska E: Hypnotic activity of diphenhydramine, methapyrile and placebo. J Clin Pharmacol 1978:18:425-431.
8. Saletu B, Griinbcrger J, Krupka M, Schuster P: Comparative double-blind, placebo-controlled sleep laboratory studies of a combination of lorazepam and diphenhydramine (SM-1014) and its single components, Curr Thcr Res 1987;42:1037-1058.
9. Saletu B, Griinbcrger J, Andcrcr P, Barbanoj MJ: Pharmacodynamic studies of a combination of lorazepam and diphenhydramine and its single components: Electroencephalograph-ic brain mapping and safety evaluation, Curr Ther Res 1988;44:909-937.
10. Griinberger J, Saletu B, Linzmaver L, Barbanoj MJ: Pharmacodynamic studies of a combination of lorazepam and diphenhydramine and its single components: Psychometric and psv-chophysiological data, Curr Thcr Res 1988:44:938-965.
11. Fels W, Roller S: Kontrollierte klinische Prii-fung des Hypnoiikums Sonmium an cinem ge-riatrischen Krankcngut, Therapiewoche Schweiz 1989:5:79-85.
12. Miihlberger F: Klinisch-expcrimenlelle Prii-fung eincs neuen Hypnotikums auf die Atcm-funktion gcsunder Probanden mil chronisch-obstruktivcm Syndrom, Schweiz Rundsch Med Prax 1992:81(25):2-4.
13. Miihlberger F, Roller S: Wirksamkcit und Ne-benwirkungen von Somnium, Informicrtc Arzt 1992;10:909-918.
14. Saletu B, Anderer P, Brandstatter N, Frey R, Griinberger J, Rldseh G, Mandl M, Wetter T, Zeitlhofer J: Insomnia in generalized anxiety disorder: Polysomnographic, psychometric and clinical investigations before, during and after therapy with a long-versus a short-half-lifc benzodiazepine (quazepam versus triazolam), Neuropsychobiology 1994:29:69-90.
15. Hamilton M: The assessment of anxiety states by rating, Br J Med Psychol 1959:32:50-55.
16. Zung WR: A rating instrument for anxiety disorders, Psychosomalics 1971:12:371-379.
17. Zung WWR: A self-rating depression scale, Arch Gen Psychiat 1965.12:63-70.
18. Merz WA, Ballmer U: Symptoms of the barbiturate/benzodiazepine withdrawal syndrome in healthy volunteers: standardized assessment by a newly developed self-rating scale, J Psychoactive Drugs 1983;15:71-84.
19. Saletu B, Wessely P, Griinbcrger J, Schultes M: Erste klinische Erfahrungen mit cinem neuen schlafanstossendcn Bcnzodiazcpin, Cinolaze-pam, mittels cines Sclbstbeurteilungsbogcns fur Schlaf-und Aufwachqualitat (SSA), Neuropsychiatric 1987;1:169-176.
20. Borbely AA: Ambulatory motor activity monitoring to study the timecourse of hypnotic action, Br J Clin Pharmacol 1984; 17(suppl):83-86.
21. Borbely AA, Ncuhaus HU, Mattmann P, Wa-ser PG: Langzcitregistricrung der Bewegungs-aktivitat: Anwendungcn in Forschung und Kli-nik, Schweiz Med Wochenschr 1981; 111:730-735.
22. Mattmann P, Loepfe M, Scheitlin T, Schmidlin D, Gcmc M, Strauch I, Lehmann D, Borbely AA: Dav-time residual effects and motor activity after three benzodiazepine hypnotics, Arz-neimittclforsch 1982:32:461-465.
23. Hauri PJ, Wisbey J: Wrist actigraphy in insomnia, Sleep 1992;15:293-301.
24. Rlosch G, Saletu B, Gruber G, Anderer P: Actigraphy in a non-24-hour slecp-wake-svndrome before and during chronobiological therapy, New Trends Exp Clin Psychiatry 1995:11:67-74.
25. Rlosch G, Gruber G, Anderer P, Saletu B: Aktigraphie bei Insomnie-Patienten: Alternative oder Erganzung zu Polysomnographic und Schlaffragchogcn?(In preparation)
26. Griinbcrger J, Saletu B, Linzmaver L, Bock G, Weissgram S, Brandstatter N, Frey R, Saletu-Zyhlarz G: Comparative studies on the effects of a combination drug lorazepam plus diphenhydramine (Somnium') versus lorazepam on the noopsyche, thymopsychc and psychophysiology in nonorganic insomnia related to generalized anxiety disorder, Meth Fin Exp Clin Pharmacol (in press).
27. Rechtschaffen A, Rales A: A Manual of Standardized Terminology, Technique and Scoring System for Sleep Stages of Human Subject, Los Angeles, Brain Information Service, University of California, 1968.
28. Reynolds CF, Taska LS, Jarrct DB, Coble PA, Rupfer DJ: REM latency in depression: Is here one best definition? Biol Psychiatry 1983:18: 849-863.
29. Von Zerssen D, Koeller DM, Rey ER: Die Befindlichkeilsskala (B-S)-Ein cinfaches Instrument zur Objcktivierung von Bcfindlich-keitsstdrungen, insbesondcre im Rahmen von Langsschnittuntersuchungen, Arzneimittelfor-schung 1970:20:915-918.
30. Griinberger J: Psychodiagnoslik des Alkohol-kranken, Ein methodischcr Beitrag zur Bestim-mung der Organizitat in der Psychiatric, Vienna, Maudrich, 1997.
31. Fiinfgeld EW: Vigorimeter: Zur Kraftmessung der Hand und zur Simulationspriifung, Dcutsch Med Wochenschr 1966;49:2214-2216.
32. Saletu B, Anderer P, Rinsperger R, Griinberger J: Topographic brain mapping of EEG in neuropsychopharmacology, 2. Clinical applications (pharmaco EEG imaging), Methods Find ExpClin Pharmacol 1987;9:385-408.
33. Anderer P, Saletu B, Rinsperger R, Semlitsch II: Topographic brain mapping of EEG in neuropsychopharmacology, 1. Methodological aspects, Methods Find Exp Clin Pharmacol 1987:9:371-384.
34. Anderer P, Semlitsch HV, Saletu B, Barbanoj MJ: Artifact processing in topographic mapping of electroencephalographic activity in neuropsvchopharmacology, Psychiatry Res 1992:45:79-93.
35. Bartels PH, Subach JA: Automated interpretation of complex scenes; in Preston E, Onoe M (eds): Digital Processing of Biomedical Imagery, New York, Academic Press, 1976. pp 101-114.
36. Dulffy FH, Bartels PH, Burchfield JL: Significance probability mapping: An aid in the topographic analysis of brain electrical activity, El-cctrocnccphalogr Clin Neurophysiol 1991:51: 455-462.
37. Abt R: Descripitive data analysis (DDA) in quantitative EEG studies; in Samson-Dollfus D, Guieu JD, Gotman J, Etevenon P (eds): Statistics and Topography in Quantitative EEG. Amsterdam, Elsevier, 1988. pp 150-160
38. Saletu-Zyhlarz G, Saletu B, Anderer P, Brandst Utter N, Frey R, Gruber G, Rlosch G, Mandl M, Griinbcrger J, Linzmaycr L: Non-organic insomnia in generalized anxiety disorder, 1. Controlled studies on sleep, awakening and daytime vigilance utilizing polysomnography and EEG mapping, Neuropsvchobiology 1997: 36:117-129.
39. Mar DD: Short-and long-acting benzodiazepines, Am J Nurs 1981:12:2200-2201.
40. Brown PJ, Forrest WH Jr. Brown CR: Lorazepam compared with pentobarbital for nighttime sedation, J Clin Pharmacol 1975; 15:752-759.
41. Hedges A, Turner P, Harry TVA: Preliminary studies on the central effects of lorazepam, a new benzodiazepine, J Clin Pharmacol 1971; 11:423-427.
42. Imlah NW: Clinical expcrinccc with lorazepam in hospital patients, Curr Med Res Opin 1973; 1:276-281.
43. Linnoila M, Viukari M, Lamminsivu U, Auvinen J: Efficacy and side effects of lorazepam, oxazepam and temazepam as sleeping aids in psychogeriatric inpatients, Int Pharmacopsychiatry 1980:15:129-135.
44. Wang RIH, Stockdale SL, Hieb E: Hypnotic activity of lorazcpam and flurazepam, Clin Pharmacol Thcr 1976;19:191-195.
45. Banen DM, Resnik O: Lorazcpam vs gluteth-imidc as a slccp-inducing agent for the geriatric patient, J AmGeriatrSoc 1973:21:507-511.
46. Scharft MB, Jacoby JA: Lorazcpam-Efficacy, side effects and rebound phenomena, Cl in Pharmacol Ther 1982;42:175-179.
47. Jaattela E, Mannisto P, Paatero H, Tuomisto J: The effects of diazepam or diphenhydramine on healthy human subjects, Psychopharmacology 1971;21:202-211.
48. Mamelak M, Csima A, Price V: Effects of qua-zepam and triazolam on the sleep of chronic insomniacs: A comparative 25-night sleep laboratory study, Clin Ncuropharmacol 1985:8: 63-73.
49. Kales A, Kales JD: Evaluation and Treatment of Insomnia, New York, Oxford University Press, 1984.
50. Saletu B, Griinberger J, Linzmaycr L: Quantitative pharmaco-EEG and performance after administration of brotizolam to healthy volunteers, Br J Clin Pharmacol 1983; 16:333-335.
51. Saletu B, Grunberger J, Taeuber K, Nitsche V: Relation between pharmacodynamics and-kinetics: EEG and psychometric studies with cinolazcpam and nomifensine: in Herrmann W (ed): Electroencephalography in Drug Research, Stuttgart, Fischer, 1982. pp 89-111.
52. Saletu B, Pakesch G: Recent advances in the clinical pharmacology of benzodiazepines, 2. Pharmacodynamics, Hum Psychopharmacol 1987;2:61-84.
53. Fontaine R, Choinard G, Annablc L: Rebound anxiety in anxious patients after abrupt withdrawal of benzodiazepine treatment, Am J Psychiatry 1984;141:848-852.
54. Mamelak M, Csima A, Price V: The effects of a single night's dosing with triazolam on sleep the following night, J Clin Pharmacol 1990:30: 549-555.
55. Murphy SM, Tyrer P: A double-blind comparison of the effects of gradual withdrawal of lorazcpam, diazepam and bromazepam in benzodiazepine dependence, Br J Psychiatry 1991: 158:511-516.
56. Reynolds JEF: Martindale, the Extra Pharmacopoeia, London, The Pharmaceutical Press, 1993.
57. Sellers EM: Comparative drug effects and abuse liability of lorazcpam, buspirone and secobarbital in nondependent subjects, J Clin Psvchopharmacol 1992; 12:79-85.
58. Preston KL: Subjective and behavioral effects of diphenhydramine, lorazcpam and methocarbamol: Evaluation of abuse liability, J Pharmacol Exp Ther 1992:262:707-720.
59. Ladewig D: Tranquilizer-Abusus-Ergcbnissc einer gesamtschweizcrischen Enquctc, Schweiz Arzteztg 1981:62:3203-3209.
60. Rickels K, Case WG, Diamond L: Relapse after short-term drug therapy in neurotic outpatients, Int Pharmacopsvchiatrv 1980:15: 186-192.
61. Rickels K, Case WG, Downing RW, Fridman R: One-vear follow-up of anxious patients treated with diazepam, J Clin Psvchopharma-coi 1986:6:32-36.
62. Rickels K, Fox IE, Greenblatt DJ: Clorazcpate and lorazcpam: Clinical improvement and rebound anxiety, Am J Psychiatry 1988:145: 312-317.
63. Rickels K, Case WG, Downing RW, Winokur A: Long-term diazepam therapy and clinical outcome, JAMA 1983;250:767-771.
64. Rickels K, Schweizer E, Csanalosi I, Case WG, Chung H: Long-term treatment of anxiety and risk of withdrawal, Prospective comparison of clorazcpate and buspirone, Arch Gen Psychiatry 1988;45:444-450.
65. Saletc B, Grunberger J, Linzmaycr L, Flener R: Anxiolytics and beta blockers: Evaluation of pharmacodynamics by quantitative EEG, psychometric and physiological variables, Aggres-sologie 1981;22:5-16.
66. Herrmann WM: Development and critical evaluation of an objective procedure for the electroencephalographic classification of psychotropic drugs: in Herrmann WM (ed): Electroencephalography in Drug Research, Stuttgart, Fischer, 1982. pp 249-351.
67. Saleti B, Brandstatter N, Mclka M, Slamen-kovie M, Andercr P, Semlitsch HV, Heytma-nek G, Huber J, Grunberger J, Linzmayer L, Kurz Ch, Decker K, Binder G, Knoglcr W, Koll B: Hormonal, syndromal and EEG mapping studies in menopausal syndrome patients with and without depression as compared with controls, Maluritas 1996:23:91-105.
68. Salete B: Psychopharmaka, Gehimtatigkeit und Schlaf, Bibl Psychiatr, Basel, Karger, 1976. No 155.